Trial Profile
Multicenter, double-blind, randomized, placebo-controlled, dose ranging phase 2 study to investigate efficacy, safety, tolerability and pharmacokinetics of the DPP-IV inhibitor RO4876904 in patients with type 2 diabetes
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Carmegliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Roche
- 25 Jul 2019 This trial has been completed in United Kingdom, according to European Clinical Trials Database.
- 02 Dec 2008 Actual completion date changed from July 2008 to March 2008 according to ClinicalTrials.gov.
- 16 Jul 2008 Status changed from in progress to completed as reported by Roche.